FDG PET for Head and Neck Cancers (Replaced with Section 220.6.17) - RETIRED | CMS Coverage Update

Summary: The Centers for Medicare & Medicaid Services modified its FDG PET coverage policy for head and neck cancers, retiring the standalone policy and replacing it with Section 220.6.17, effective May 15, 2026. Here's what billing teams need to do before that date.

This change affects how Medicare covers FDG-PET (fluorodeoxyglucose positron emission tomography) imaging for head and neck cancer indications. The old standalone policy is gone. Coverage now lives under Section 220.6.17 of the Medicare National Coverage Determinations manual. The policy does not list specific CPT or HCPCS codes in the data provided — we'll address what that means for your claim preparation below.

CMS FDG PET Head and Neck Cancer Coverage Criteria and Medical Necessity Requirements 2026

The core issue here is structural. CMS retired a standalone policy and folded FDG PET head and neck cancer coverage into Section 220.6.17 — its consolidated NCD for oncologic PET imaging. This is a policy consolidation, not a coverage expansion or restriction on its face. But that distinction matters less than you might think. When the policy document changes, so does the reference your billing team uses to defend medical necessity on appeal.

If your practice or facility has internal documentation, coding checklists, or prior authorization templates that reference the old standalone FDG PET head and neck policy, those references are now pointing at a retired document. A claim denial based on a policy your team cited incorrectly is hard to appeal, especially when CMS can point to the retirement date.

The CMS FDG PET head and neck cancer coverage policy has historically required that FDG-PET imaging be ordered for specific oncologic indications — initial staging, monitoring response to treatment, and restaging after completed therapy. Medical necessity under the NCD framework requires a treating physician's order tied to a covered indication. That framework carries forward into Section 220.6.17, but you should confirm the exact criteria in the new section rather than assuming a one-to-one carryover.

Prior authorization is not a standard CMS requirement for PET imaging under Medicare fee-for-service. However, Medicare Advantage plans — and any managed care products built on Medicare coverage policy — may apply their own prior authorization rules. Check your contracted MA plans now. If they were referencing the retired standalone policy in their own PA criteria, they may or may not have updated to Section 220.6.17 yet.

The broader CMS FDG PET oncology coverage policy framework under Section 220.6.17 distinguishes between covered indications and those considered not medically necessary or not covered. Head and neck cancers have historically been among the better-covered oncologic indications for PET imaging — these are tumors where FDG-PET has strong clinical evidence for staging and restaging. The retirement of the standalone policy doesn't signal a retreat from that coverage. It signals administrative consolidation. But billing teams should never assume continuity — verify it.

Coverage Indications at a Glance

The policy data provided does not include a detailed breakdown of covered versus non-covered indications from Section 220.6.17. The table below reflects the general CMS oncologic PET imaging framework as it applies to head and neck cancers. Confirm specifics against the full Section 220.6.17 text before May 15, 2026.

CPT, HCPCS, and ICD-10 Codes for FDG PET Head and Neck Cancer Under This Policy

The policy data provided for this change does not list specific CPT, HCPCS, or ICD-10 codes. Do not assume the codes have changed — but do not assume they haven't, either.

What to Do When No Codes Are Listed

This is actually a signal, not an oversight. Policy retirements and consolidations frequently don't re-enumerate codes because the assumption is that code coverage follows the indication criteria into the new section. That assumption has burned billing teams before.

Pull the full text of Section 220.6.17 from the CMS NCD manual. Identify every CPT and HCPCS code explicitly listed or referenced. Cross-reference that list against what your team currently bills for FDG PET imaging in head and neck cancer cases. If a code your team uses regularly doesn't appear in 220.6.17, flag it for your compliance officer before May 15, 2026.

Common PET imaging codes used in head and neck oncology billing — including codes in the 78xxx nuclear medicine range — should be verified against Section 220.6.17 directly. PayerPolicy will update this post with the specific codes from Section 220.6.17 as the full policy text is confirmed.

CMS FDG PET Billing Guidelines and Action Items 2026

Here's what your billing and revenue cycle team should do right now. Don't wait until May.

Why This Change Matters More Than It Looks

Policy retirements are easy to dismiss. Nothing changed, right? The coverage is just moving to a new home.

That framing is wrong, and it costs practices money.

When CMS retires a standalone policy and consolidates it, the new section often has slightly different language — sometimes intentionally, sometimes as a drafting artifact. "Slightly different" in NCD language can mean a covered indication that was explicit in the old policy is now implied in the new one. Implied coverage is harder to defend on appeal than explicit coverage.

The real issue here isn't whether FDG PET for head and neck cancers is still covered under Medicare. It almost certainly is, for the same indications it was covered for before. The real issue is whether your team's documentation, templates, and appeal language keep pace with where CMS officially houses that coverage.

Claim denial patterns often lag policy changes by 60 to 90 days. If your team doesn't update references before May 15, 2026, you'll likely see clean claims for the first few billing cycles — and then start seeing denials that are harder to trace back to a root cause. Auditors and reviewers who work from the current NCD manual will cite Section 220.6.17. If your team is still citing the retired policy, the disconnect shows.

FDG PET billing is already a high-scrutiny area. These are high-cost studies, and Medicare reviews them closely. Any ambiguity in your documentation or policy citations gives reviewers an opening. Close that opening before May 15.